New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2013
15:26 EDTNYCB, DELL, CELG, EXPR, GMCRStocks with expanding option implied volatility; EXPR DELL GMCR CELG NYCB
News For EXPR;DELL;GMCR;CELG;NYCB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 19, 2014
16:01 EDTGMCRKeurig Green Mountain raises dividend 15%
Subscribe for More Information
16:00 EDTGMCRKeurig Green Mountain reports Q4 adjusted EPS 90c, consensus 77c
Subscribe for More Information
15:31 EDTGMCRNotable companies reporting after market close
Subscribe for More Information
14:40 EDTGMCRKeurig Green Mountain technical comments ahead of results
Subscribe for More Information
14:08 EDTGMCREarnings Preview: Keurig Green Mountain sees FY14 EPS $3.71-$3.78
Subscribe for More Information
13:26 EDTGMCRKeurig Green Mountain November 155 straddle priced for 8.7% move into Q4
10:47 EDTGMCRStocks with call strike movement; GME GMCR
GameStop (GME) December 55 call option implied volatility increased 4% to 55, Green Mountain (GMCR) December 185 call option implied volatility increased 3% to 54 according to IVolatility.
09:39 EDTCELGCelgene management to meet with ISI Group
Subscribe for More Information
November 18, 2014
08:07 EDTGMCRGreen Mountain Coffee volatility elevated into Q3 and outlook
Green Mountain Coffee November call option implied volatility is at 101, December is at 50, January is at 45, March is at 43; compared to its 26-week average of 42 according to Track Data, suggesting large near term price movement into the expected release of Q3 results on November 19.
07:50 EDTGMCRKeurig Green Mountain price target raised to $168 from $134 at Canaccord
Subscribe for More Information
07:34 EDTCELGCelgene presents long-term OTEZLA data at ACR/ARHP meeting
Celgene announced that results from long-term efficacy and safety analyses of OTEZLA from the open-label phase of two PALACE phase III clinical trials were presented at the 2014 American College of Rheumatology/Association of Rheumatology Health Professionals annual meeting in Boston. OTEZLA is the Company’s oral, selective inhibitor of phosphodiesterase 4, approved by the U.S. FDA for the treatment of adult patients with active psoriatic arthritis and for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. In PALACE 1, 84 percent of patients who completed one year of 30 mg twice daily therapy continued to receive OTEZLA at two years. Improvements in efficacy measures observed at 52 weeks were sustained through 104 weeks of treatment. At week 104, among patients receiving OTEZLA 30 mg twice daily, the ACR20 response rate was 65.3 percent. ACR50 and 70 response rates were 34.0 percent and 19.6 percent, respectively, at week 104. Similar findings were observed in PALACE 4. In this trial, nearly 84 percent of DMARD-naïve patients who completed one year of OTEZLA 30 mg twice daily monotherapy continued to receive OTEZLA at two years. At week 104, among patients treated with OTEZLA 30 mg twice daily monotherapy, an ACR20, 50 and 70 response was reached by 61.4 percent, 40.7 percent and 19.2 percent of patients, respectively. In both PALACE 1 and PALACE 4, changes in other efficacy measures—including the HAQ-DI, which assesses improvements in physical function, and swollen and tender joint counts—were also generally sustained between weeks 52 and 104 with continued OTEZLA treatment. In PALACE 4, treatment with OTEZLA in patients with pre-existing enthesitis or dactylitis, two key manifestations of psoriatic arthritis, resulted in improvements in enthesitis and dactylitis that were sustained through 104 weeks of treatment.
November 17, 2014
07:26 EDTGMCRBofA/Merrill expects in-line Q4 report from Keurig Green Mountain
Subscribe for More Information
07:16 EDTCELGMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
November 14, 2014
17:07 EDTCELGSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
09:05 EDTGMCRKeurig Green Mountain target to $185, Cold may be a disrupter, says Goldman
Subscribe for More Information
08:31 EDTGMCRGreen Mountain Coffee November volatility elevated into Q3 and outlook
Subscribe for More Information
07:14 EDTCELGAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
November 11, 2014
11:40 EDTGMCRStocks with call strike movement; FSLR GMCR
Subscribe for More Information
November 10, 2014
15:43 EDTDELLAmerican Petroleum Institute to hold a conference
Subscribe for More Information
07:19 EDTCELGCredit Suisse to hold a conference
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use